Cart
sales@molnova.com
TFAP
CAS No. 1011244-68-0
TFAP( TFAP )
Catalog No. M19375 CAS No. 1011244-68-0
TFAP is a selective cyclooxygenase-1 (COX-1) inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 65 | In Stock |
|
| 10MG | 102 | In Stock |
|
| 25MG | 196 | In Stock |
|
| 50MG | 356 | In Stock |
|
| 100MG | 530 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTFAP
-
NoteResearch use only, not for human use.
-
Brief DescriptionTFAP is a selective cyclooxygenase-1 (COX-1) inhibitor.
-
DescriptionTFAP is a cell-permeable pyridinyl-benzamide compound that acts as a COX-1-selective inhibitor by targeting the enzyme's active site. TFAP displays analgesic properties in mice and rats in vivo without long-term cytotoxic effects. Unlike COX-2-inhibiting analgesics such as aspirin, TFAP is shown not to cause gastric damage in rats in vivo.
-
In VitroTFAP is a selective cyclooxygenase-1 (COX-1) inhibitor, with an IC50 of 0.8 μM, while that against COX-2 is over 200 μM.
-
In Vivo——
-
SynonymsTFAP
-
PathwayChromatin/Epigenetic
-
TargetCOX
-
RecptorCOX-1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1011244-68-0
-
Formula Weight281.23
-
Molecular FormulaC13H10F3N3O
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 155 mg/mL; 551.15 mM
-
SMILESO=C(Nc1ccc(N)cn1)c2ccc(cc2)C(F)(F)F
-
Chemical NameN-(5-amino-2-pyridinyl)-4-(trifluoromethyl)-benzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kakuta H, et al. Identification of urine metabolites of TFAP, a cyclooxygenase-1 inhibitor. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1840-3.
molnova catalog
related products
-
Sulindac
Sulindac is a nonsteroidal anti-inflammatory agent (NSAIA) of the arylalkanoic acid class that is marketed in the U.S. by Merck as Clinoril.
-
Chemocoxib A
Chemocoxib A is a highly potent, selective, cytotoxic COX-2 inhibitor with IC50 of 290 nM and 90 nM for wt mCOX-2 and R120Q COX-2 mutant respectively.
-
Orientin
Orientin may be regarded as a candidate therapeutic agent for treatment of vascular inflammatory diseases via inhibition of the HMGB1 signaling pathway.
